Alpha 2.0
Login Register
» Articles » PMID: 16455939

Treatment Failure Resulting from Resistance of Staphylococcus Aureus to Daptomycin

Overview
Journal J Clin Microbiol
Specialty Microbiology
Date 2006 Feb 4
PMID 16455939
Citations 70
Authors
Daniel J Skiest
Affiliations
Soon will be listed here.
Abstract

Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.

Citing Articles

Phenotypic and genetic characterization of daptomycin non-susceptible strains selected by adaptive laboratory evolution.

Xu Y, Xiao Y, Zhao H, Wang B, Yu J, Shang Y Front Cell Infect Microbiol. 2024; 14:1453233.

PMID: 39512591 PMC: 11540788. DOI: 10.3389/fcimb.2024.1453233.

Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.

Hammond J, Benigno M, Bleibdrey N, Ansari W, Nguyen J Drugs Real World Outcomes. 2024; 11(2):273-283.

PMID: 38564101 PMC: 11176132. DOI: 10.1007/s40801-024-00422-5.

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin.

Kebriaei R, Abdul-Mutakabbir J, Stamper K, Lev K, Rybak M Infect Dis Ther. 2023; 12(10):2485-2494.

PMID: 37798469 PMC: 10600059. DOI: 10.1007/s40121-023-00875-1.

Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant .

Yang J, Brown C, Noland W, Johnson T, Ji Y Antibiotics (Basel). 2022; 11(11).

PMID: 36358205 PMC: 9686779. DOI: 10.3390/antibiotics11111550.

Impact of PrsA on membrane lipid composition during daptomycin-resistance-mediated β-lactam sensitization in clinical MRSA strains.

de Carvalho C, Taglialegna A, Rosato A J Antimicrob Chemother. 2021; 77(1):135-147.

PMID: 34618036 PMC: 8730685. DOI: 10.1093/jac/dkab356.

References
1.
Rybak M, Hershberger E, MOLDOVAN T, Grucz R . In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 2000; 44(4):1062-6. PMC: 89814. DOI: 10.1128/AAC.44.4.1062-1066.2000. View
2.
Steenbergen J, Alder J, Thorne G, Tally F . Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005; 55(3):283-8. DOI: 10.1093/jac/dkh546. View
3.
Mangili A, Bica I, Snydman D, Hamer D . Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005; 40(7):1058-60. DOI: 10.1086/428616. View
4.
Richter S, Kealey D, Murray C, Heilmann K, Coffman S, Doern G . The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2003; 52(1):123-7. DOI: 10.1093/jac/dkg288. View
5.
Silverman J, Oliver N, Andrew T, Li T . Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001; 45(6):1799-802. PMC: 90548. DOI: 10.1128/AAC.45.6.1799-1802.2001. View